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ABSTRACTSThus inhibition of p63-related signalling coupled with standard therapies
could result in a blockade of tumour progression, even in castrate resistant
prostate cancer where only limited therapeutic options are available.
SARS ACADEMIC AND RESEARCH PRIZE: 1159: PHOTOCHEMICAL INTER-
NALISATION AS A DELIVERY TOOL TO IMPROVE CHEMOTHERAPY FOR
ORAL SQUAMOUS CELL CARCINOMA
Ishita Basu, Alexander MacRobert, Colin Hopper. University College London,
London, UK.
Background & Aims: Photochemical internalisation (PCI) is based on
photodynamic therapy (PDT), and is a light-activated drug delivery tech-
nique that increases the bioavailability of therapeutic drugs through
photosensitised intracellular release of drugs entrapped within endocytic
vesicles. PCI reduces the toxicity in non-target tissues.
The aim of this study was to compare the cytotoxicity of PDT and PCI on an
oral squamous cell carcinoma cell line (HCPC-1) in vitro.
Method: The HCPC-1 cell line, developed from a hamster buccal pouch
carcinoma was used. The ribosome inactivating protein (RIP) toxin, sap-
orin, was used with the photosensitiser, disulfonated tetraphenylporphine
(TPPS2a). Blue light was used for PDT and combined with saporin for PCI.
Viability was assessed with the MTT assay.
Results: The PCI cytotoxicity was signiﬁcantly higher than PDT (P<
0.0001) and saporin (P < 0.0001) separately. The ratio to assess synergy A/
C x B, using cell viability, (A¼saporin, B¼PDT, C¼PCI) for HCPC-1 cells was
calculated to be 1.04, thus showing a PCI effect.
Conclusion: PCI is able to induce the relocalisation of saporin within cells
and therefore enhance cell death in HCPC-1 cells. PCI was also shown to be
signiﬁcantly more cytotoxic than PDT on the HCPC-1 oral cancer cell line.
SARS ACADEMIC AND RESEARCH PRIZE: 1423: A COMPARATIVE STUDY
OF THE PROGNOSTIC ROLE OF KI67 AND GEMININ IN BREAST CANCER
Sreekumar Sundara Rajan 1, Andrew Hanby 1, Kieran Horgan 1,
Valerie Speirs 2. 1 Leeds Teaching Hospitals NHS Trust, Leeds, UK; 2 Leeds
Institute of Molecular Medicine, University of Leeds, Leeds, UK.
Aims: Compared to other markers of cell proliferation, geminin is unique
being expressed selectively during the proliferative phase of the cell cycle.
We aimed to compare the prognostic signiﬁcance of geminin with that of
Ki67 and other common clinico-pathological variables.
Methods: Tissue microarrays containing 291 breast tumours were stained
using anti-geminin antibody (NCL-L; 1:12.5) and Ki67 (MIB1; 1:100).
Labelling index (LI) was calculated for geminin and the percentage of
positive cancer nuclei were determined for Ki67 expression. ROC curve
was used to determine the optimum cut-off value for geminin (LI  2) and
Ki67 ( 2.25%) for survival analysis.
Results: Geminin expression was positively correlated with Ki67 expres-
sion (r ¼ 0.686, p ¼ 0.001). Survival analysis showed poor BCSS and DFS
amongst cases positive for geminin [BCSS-HR 2.85 (1.53, 5.32); DFS-
HR¼2.63 (1.47, 4.71)] and Ki67 [BCSS-HR 2.62 (1.53, 4.48); DFS-HR 2.28
(1.39, 3.77)]. However on multivariate analysis, only geminin LI (DFS,
p¼0.04 (CI 1.01, 4.32); BCSS, p¼0.0003 (CI 1.79, 7.53)), nodal status, tumour
size and grade were found to be independent predictors.
Conclusions: In comparison to more established proliferation marker like
Ki67, geminin expression is a strong and independent predictor of adverse
outcome in breast cancer.
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Cancer Institute, NUI Galway, USA.
Introduction: Treatment options for TNBC are limited due to the lack of a
therapeutic target and are managed with standard chemotherapy such as
paclitaxel (Taxol(R)).
Decreased expression of the mitotic assembly deﬁcient protein (MAD2)
results in the induction of cellular senescence, demonstrable by enhanced
chemoresistance to paclitaxel (Taxol(R)). We hypothesize that low MAD2 is
predictive of poor response to chemotherapy.
Methods: 81 ER-negative tumours from an established US cohort were
assessed for MAD2 expression using immunohistochemistry. Kaplan-
Meier graphs and log-rank tests were used to display breast cancer sur-
vival. Proportional hazards cox regression was used to estimate hazard
ratios and conduct univariate and mutivariable analysis.
Results: Patients with high levels of MAD2 display increased breast cancer
speciﬁc survival (HRHighMAD2: 0.34, 95%CI 0.15-0.76, p¼0.008). Patients
with lowMAD2 do poorly. MAD2 prediction of outcome is limited to those
who received chemotherapy (Chemo: HRHighMAD2: 0.31, 95%CI 0.12-0.80,
p¼0.015; No chemo: HRHighMAD2: 1.03, 95%CI 0.10-10.6, p¼0.978), or
radiotherapy (Radiother: HRHighMAD2: 0.24, 95%CI 0.06-0.85, p¼0.027; No
radiother: HRHighMAD2: 0.48, 95%CI 0.15-1.51, p¼0.210). MAD2 expression is
predictive in patients who received both chemotherapy and radiotherapy
(HRHighMAD2: 0.09, 95%CI 0.02-0.45, p¼0.003).
Conclusion: We believe MAD2 is a predictor of poor outcome after
chemotherapy and radiotherapy in TNBC.ASIT SHORT PAPER PRIZE: 0044: THE USE OF ULTRASOUND FOR THE
ACUTE ABDOMEN IN THE SURGICAL ADMISSIONS UNIT (SAU)
Jana Torres-Grau, Richard Krysztopic. Royal United Hospital Bath, Bath, UK.
Objective: To improve the quality and efﬁciency of emergency surgical
services and reduce inpatient stay.
Introduction: Our surgical Admission Unit is a 27-bed-ward. When an
ultrasound is required, this is ordered to the radiology department. Time is
then spent prioritising the cases, and transferring the patient. We
hypothesised that a SAU based ultrasound would reduce time to diagnosis,
and consequently inpatient stay.
Methods: We had a 4-week period with a SAU-based radiographer, and
then a 4-week period of ultrasound performed in the radiology depart-
ment. Time to ultrasound, diagnosis and length of inpatient stay were
recorded and compared.
Results: Time to USS with ward based radiographer (group1) was 1hr 38
min compared to 36hr 25 min in the radiology department (group2) (p-
value 0.0001). The total inpatient-stay for group1 was 103hrs compared
with 159hrs for group2 (p-value 0.0001). A total of over 2 days less hos-
pital-stay for those who had an ultrasound while in SAU.
Conclusion: SAU based ultrasound hastens time to correct diagnosis,
treatment and or further investigations, and reduces the length of inpa-
tient stay, a mean of over 2 days. This is a signiﬁcant economical advantage
and improves the quality and efﬁciency of surgical emergency services,
being transferrable nationally.ASIT SHORT PAPER PRIZE: 0091: ASGBI/ASIT SHORT PAPER PRIZE
WINNER: FACTORS ASSOCIATED WITH MORTALITY WITHIN 1-YEAR
FOLLOWING A DISPLACED INTRACAPSULAR NECK OF FEMUR
FRACTURE
Maulik Gandhi, Swati Bhasin, Sohail Quraishi. Dudley Group of Hospitals,
Dudley, UK.
Introduction: Worldwide hip fracture incidence is projected to be 4.5
million by 2050. We analysed our hip fracture database to highlight factors
that (1) increased mortality within 1-year from admission; (2) correlate
with survival period.
Methods: Inclusions: Displaced intracapsular hip fractures between
August 2008 and July 2012. Exclusions: Admissions less than 1-year ago
and not reported deceased. Factors analysed: Nottingham Hip Fracture
Score (NHFS), age, admission haemoglobin (Hb), preadmission walking
ability outdoors, indoors (independent, one stick, two sticks or frame, bed/
wheelchair bound), gender and fracture side.
Results: Eligible patients ¼ 477. Signiﬁcance: NHFS (p < 0.001), age
(p¼0.0000), Hb result (p¼0.0019), walking ability outdoors (p< 0.001),
